Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P19827

UPID:
ITIH1_HUMAN

ALTERNATIVE NAMES:
Inter-alpha-trypsin inhibitor complex component III; Serum-derived hyaluronan-associated protein

ALTERNATIVE UPACC:
P19827; A8K9N5; B2RAH9; B7Z558; B7Z8C0; F5H165; F5H7Y8; P78455; Q01746; Q562G1

BACKGROUND:
The protein Inter-alpha-trypsin inhibitor heavy chain H1, alternatively known as Serum-derived hyaluronan-associated protein, is implicated in the transport and regulation of hyaluronan within the serum. It acts as a bridge between hyaluronan and matrix proteins, crucial for cell processes. The protein also harbors a peptide with the potential to activate various phagocytotic cells, underscoring its significance in immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Inter-alpha-trypsin inhibitor heavy chain H1 offers a promising avenue for therapeutic intervention. Its key role in managing hyaluronan dynamics and stimulating immune cells provides a foundation for novel drug discovery efforts aimed at these critical biological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.